"Lilly debuts more Foundayo data as FDA requests post-marketing trials" was originally created and published by ...

Lilly plans to file Foundayo with the FDA for type 2 diabetes by end of Q2 after the ACHIEVE-4 trial met its primary ...

By Sriparna Roy and Sahil Pandey April 16 (Reuters) - Eli Lilly said on Thursday its newly approved obesity pill was not ...

Foundayo was approved in the U.S. on April 1, with prescriptions accepted immediately on LillyDirect, while shipping started ...

The pharmaceutical’s Foundayo drug takes on oral Wegovy, the popular treatment from Novo Nordisk.

The results seen with Foundayo, also known as orforglipron, enabled Lilly’s late-stage Achieve-4 study to hit its primary ...

Eli Lilly has another promising drug in its portfolio with Foundayo. Its growth rate has been more than 40% in recent ...

Right after the FDA flagged safety concerns for Eli Lilly’s newly approved obesity pill, the pharma posted diabetes data ...

Even as Eli Lilly gets underway with its next major obesity launch in Foundayo, an FDA document related to the oral treatment ...

At the heart of the request is whether taking Foundayo - made with a new active ingredient called orforglipron - could be ...

Eli Lilly says it has the safety data it needs to shore up the recent speedy approval of its oral obesity therapy Foundayo, ...